DMAAR Swings to Profit on Trust Account Interest, Hunts Pharma Target

TL;DR

**DMAAR is flush with cash and earning big interest, making it a solid bet to find a pharma deal before its deadline.**

AI Summary

Drugs Made In America Acquisition Corp. (DMAAR) reported a net income of $5,727,685 for the nine months ended September 30, 2025, a significant turnaround from a net loss of $199,859 for the period from inception (May 23, 2024) through September 30, 2024. This positive shift was primarily driven by $6,454,232 in interest earned on cash and investments held in its Trust Account, offsetting $726,547 in general and administrative costs. The company successfully completed its Initial Public Offering on January 29, 2025, raising $200,000,000, and an additional $30,000,000 from the underwriters' over-allotment option on February 18, 2025. A total of $231,150,000 was placed in the Trust Account, invested in U.S. government treasury obligations. The company also sold 430,000 Private Placement Units to its Sponsor for $4,300,000, though $608,822 remains as a share subscription receivable. DMAAR is a blank check company focused on the pharmaceutical industry and has until April 29, 2026, with potential extensions, to complete a business combination.

Why It Matters

This 10-Q reveals DMAAR's strong financial position, with over $237 million in assets, primarily in its Trust Account, generating substantial interest income. For investors, this indicates a well-funded SPAC with a clear runway to pursue a business combination in the pharmaceutical sector. The company's ability to generate significant non-operating income from its trust account provides a buffer against operational costs and enhances shareholder value, making it an attractive vehicle for potential target companies. The competitive landscape for SPACs remains intense, and DMAAR's robust cash position and focus on a specific industry could give it an edge in securing a desirable acquisition, impacting employees and customers of any future merged entity.

Risk Assessment

Risk Level: medium — The company is a blank check company with no operations, meaning its success hinges entirely on completing a Business Combination. While it holds $237,604,232 in its Trust Account, there is no assurance a suitable target will be identified or that a combination will be successful, as stated in Note 1. The company also has a deferred underwriting fee payable of $6,900,000, which could impact its financial flexibility if a deal doesn't materialize.

Analyst Insight

Investors should monitor DMAAR's progress in identifying a target company within the pharmaceutical industry. Given its strong cash position and interest income, it presents a relatively stable SPAC investment, but the ultimate return depends on the quality and valuation of its eventual business combination. Consider holding if you believe in the management's ability to execute a strategic acquisition in the pharma space.

Financial Highlights

debt To Equity

N/A

revenue

$0

operating Margin

N/A

total Assets

$237,632,428

total Debt

$7,356,611

net Income

$5,727,685

eps

$0.19

gross Margin

N/A

cash Position

$237,604,232

revenue Growth

N/A

Key Numbers

• $5.7M — Net Income (For the nine months ended September 30, 2025, a significant increase from a $199,859 loss in the prior period.)
• $237.6M — Cash and investments in Trust Account (As of September 30, 2025, representing the primary asset base for a business combination.)
• $6.45M — Interest earned on Trust Account (For the nine months ended September 30, 2025, driving the company's profitability.)
• $6.9M — Deferred underwriting fee payable (A significant liability contingent on completing a business combination.)
• 23M — Redeemable ordinary shares outstanding (As of September 30, 2025, with a redemption value of $10.33 per share.)
• $0.19 — Basic and diluted net income per redeemable ordinary share (For the nine months ended September 30, 2025, reflecting the interest income.)
• April 29, 2026 — Business Combination Deadline (Initial deadline, with potential extensions up to 21 months total.)
• $608,822 — Share subscription receivable (Amount owed by the Sponsor as of September 30, 2025.)

Key Players & Entities

• Drugs Made In America Acquisition Corp. (company) — registrant
• Drugs Made In America Acquisition LLC (company) — Sponsor
• Nasdaq Stock Market LLC (company) — exchange for securities
• SEC (regulator) — filing authority
• $231,150,000 (dollar_amount) — amount in Trust Account
• $5,727,685 (dollar_amount) — net income for nine months ended Sept 30, 2025
• $6,454,232 (dollar_amount) — interest earned on Trust Account
• $6,900,000 (dollar_amount) — deferred underwriting fee payable
• $608,822 (dollar_amount) — share subscription receivable
• Cayman Islands (company) — jurisdiction of incorporation

FAQ

Risk Factors

• Dependence on Trust Account Investments [medium — financial]: The company's profitability is heavily reliant on interest earned from its Trust Account, which held $237,604,232 in U.S. government treasury obligations as of September 30, 2025. This income, amounting to $6,454,232 for the nine months ended September 30, 2025, is a primary driver of net income. Any adverse changes in interest rates or the performance of these investments could significantly impact the company's financial results.
• Business Combination Deadline [high — operational]: DMAAR has a limited timeframe, with an initial deadline of April 29, 2026, to complete a business combination. Failure to identify and complete a suitable acquisition within this period could result in the liquidation of the company and return of funds to shareholders, impacting the company's long-term viability.
• Shareholder Redemptions [medium — financial]: A significant portion of the company's capital is comprised of redeemable ordinary shares, totaling 23,000,000 shares as of September 30, 2025, with a redemption value of $10.33 per share. A high redemption rate upon a business combination could deplete the available capital for the target company, potentially jeopardizing the transaction.
• Deferred Underwriting Fee [medium — financial]: The company has a deferred underwriting fee payable of $6,900,000, which is contingent upon the completion of a business combination. This represents a substantial liability that will be triggered upon a successful merger, impacting the net proceeds available to the combined entity.
• Share Subscription Receivable [low — financial]: As of September 30, 2025, there is a $608,822 share subscription receivable from the Sponsor. The collectibility of this amount is crucial for the company's working capital and could impact its ability to meet short-term obligations if not resolved.

Industry Context

Drugs Made In America Acquisition Corp. operates within the dynamic pharmaceutical and biotechnology sector, characterized by rapid innovation, significant R&D investment, and stringent regulatory oversight. The industry is driven by the pursuit of novel therapies and treatments for unmet medical needs. Companies in this space face intense competition from established pharmaceutical giants, emerging biotech firms, and academic research institutions, all vying for market share and scientific breakthroughs.

Regulatory Implications

As a blank check company targeting the pharmaceutical industry, DMAAR and its potential acquisition targets are subject to extensive regulatory scrutiny from bodies like the FDA. Compliance with Good Manufacturing Practices (GMP), clinical trial regulations, and post-market surveillance is critical. Any target company must demonstrate robust adherence to these regulations to ensure product safety, efficacy, and market access, with non-compliance posing significant financial and operational risks.

What Investors Should Do

1. Monitor the progress of the business combination search and evaluate the strategic fit and financial viability of any proposed target company.
2. Assess the impact of potential shareholder redemptions on the capital available for the business combination and the post-merger entity's financial health.
3. Analyze the company's reliance on interest income from the Trust Account and consider the implications of interest rate fluctuations on future profitability.
4. Review the terms and conditions of the deferred underwriting fee and its potential impact on the net proceeds of a business combination.

Key Dates

• 2025-01-29: Initial Public Offering (IPO) completed — Raised $200,000,000, providing capital for business combination efforts.
• 2025-02-18: Underwriters' over-allotment option exercised — Raised an additional $30,000,000, increasing the total capital available.
• 2025-09-30: Quarterly period end — Reported net income of $5,727,685, driven by interest income from Trust Account investments.
• 2026-04-29: Initial Business Combination Deadline — Company must complete a business combination by this date, with potential extensions.

Glossary

Trust Account

A segregated account holding funds raised from the IPO, typically invested in U.S. government treasury obligations, to be used for a business combination or returned to shareholders. (The primary asset of DMAAR, generating significant interest income and serving as the capital for the intended acquisition.)

Redeemable Ordinary Shares

Shares that holders have the right to redeem for a specified amount, usually the IPO price plus accrued interest, upon the occurrence of certain events, such as a business combination or liquidation. (Represents a significant portion of DMAAR's capital structure, with 23,000,000 shares outstanding as of September 30, 2025, impacting the company's financial obligations.)

Blank Check Company

A company with no commercial operations that is formed to raise capital through an initial public offering (IPO) for the purpose of acquiring an existing company. (Describes DMAAR's business model, highlighting its focus on identifying and merging with a target company in the pharmaceutical industry.)

Sponsor

An entity or individual that organizes and finances a special purpose acquisition company (SPAC), often receiving founder shares and warrants in exchange for their investment and expertise. (The Sponsor of DMAAR is involved in private placement units and has a share subscription receivable, indicating their role in the company's formation and funding.)

Deferred Underwriting Fee

A portion of the underwriting fees that is not paid at the time of the IPO but is contingent upon the completion of a business combination. (A significant liability for DMAAR, amounting to $6,900,000, payable only upon a successful merger.)

Share Subscription Receivable

An amount owed to the company by a subscriber for shares that have been agreed to be purchased but for which payment has not yet been received. (DMAAR has a $608,822 receivable from its Sponsor, representing funds due for share purchases.)

Year-Over-Year Comparison

This filing represents a significant shift from the prior period (inception through September 30, 2024), which reported a net loss of $199,859. The current period shows a substantial net income of $5,727,685, primarily driven by $6,454,232 in interest earned on the Trust Account following the successful IPO. Total assets have surged from $550,824 to $237,632,428, reflecting the capital raised and placed in the Trust Account. Liabilities have also increased, notably with the addition of a $6,900,000 deferred underwriting fee payable, contingent on a business combination.

Filing Documents

• ea0264976-10q_drugs.htm (10-Q) — 805KB
• ea026497601ex31-1_drugs.htm (EX-31.1) — 14KB
• ea026497601ex31-2_drugs.htm (EX-31.2) — 14KB
• ea026497601ex32-1_drugs.htm (EX-32.1) — 6KB
• ea026497601ex32-2_drugs.htm (EX-32.2) — 6KB
• 0001213900-25-112096.txt ( ) — 4447KB
• dmaau-20250930.xsd (EX-101.SCH) — 46KB
• dmaau-20250930_cal.xml (EX-101.CAL) — 18KB
• dmaau-20250930_def.xml (EX-101.DEF) — 196KB
• dmaau-20250930_lab.xml (EX-101.LAB) — 349KB
• dmaau-20250930_pre.xml (EX-101.PRE) — 200KB
• ea0264976-10q_drugs_htm.xml (XML) — 543KB

Signatures

Signatures 26 i PART I – FINANCIAL INFORMATION Item 1. Interim Financial Statements. DRUGS MADE IN AMERICA ACQUISITION CORP. BALANCE SHEETS (UNAUDITED) September 30, 2025 December 31, 2024 ASSETS Current assets Cash $ 717 $ 1,351 Prepaid expenses and other current assets 27,479 3,640 Total Current Assets 28,196 4,991 Deferred offering costs — 545,833 Cash and investments held in Trust Account 237,604,232 — TOTAL ASSETS $ 237,632,428 $ 550,824 LIABILITIES AND SHAREHOLDERS' DEFICIT Current liabilities Accounts payable and accrued expenses $ 302,623 $ 77,280 Accrued offering costs 153,988 56,065 Promissory note – related party — 662,324 Total Current Liabilities 456,611 795,669 Deferred underwriting fee payable 6,900,000 — Total Liabilities 7,356,611 795,669 Commitments Ordinary shares subject to possible redemption, 23,000,000 shares at redemption value of $ 10.33 and $ 0 per share as of September 30, 2025 and December 31, 2024, respectively 237,604,232 — Shareholders' Deficit Preference shares, $ 0.0001 par value; 1,000,000 shares authorized; none issued or outstanding as of September 30, 2025 and December 31, 2024 — — Ordinary shares, $ 0.0001 par value; 220,000,000 shares authorized; 10,517,143 and 9,857,143 shares issued and outstanding, excluding 23,000,000 and 0 shares subject to redemption as of September 30, 2025 and December 31, 2024, respectively 1,052 986 Share subscription receivable ( 608,822 ) — Additional paid-in capital — 34,014 Accumulated deficit ( 6,720,645 ) ( 279,845 ) Total Shareholders' Deficit ( 7,328,415 ) ( 244,845 ) TOTAL LIABILITIES AND SHAREHOLDERS' DEFICIT $ 237,632,428 $ 550,824 The accompanying notes are an integral part of the unaudited financial statements. 1 DRUGS MADE IN AMERICA ACQUISITION CORP. OF OPERATIONS (UNAUDITED) Three Months Ended September 30, 2025 Nine Months Ended September 30, 2025 Three M

View Full Filing

View this 10-Q filing on SEC EDGAR